Related Experiment Video

Updated: Feb 18, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.3K

Novel chimeric parapoxvirus CF189 as an oncolytic immunotherapy in triple-negative breast cancer

Audrey H Choi1, Michael P O'Leary1, Shyambabu Chaurasiya1

  • 1Department of Surgery, City of Hope National Medical Center, Duarte, CA.

Surgery
|November 28, 2017
PubMed
Abstract

Insights

A novel chimeric parapoxvirus (CF189) effectively kills triple-negative breast cancer cells in vitro and reduces tumor size in vivo. This virus shows promise as a potent new treatment for triple-negative breast cancer.

Area of Science:

  • Virology
  • Oncology
  • Biotechnology

Background:

  • Triple-negative breast cancer (TNBC) is an aggressive subtype with poor prognosis.
  • Novel therapeutic strategies are urgently needed for TNBC.
  • Genetically engineered viruses offer a promising avenue for cancer treatment.

Purpose of the Study:

  • To develop and evaluate a novel, genetically engineered parapoxvirus for its efficacy against triple-negative breast cancer.
  • To assess the in vitro and in vivo antitumor activity of the chimeric parapoxvirus CF189.

Main Methods:

  • A chimeric parapoxvirus (CF189) was engineered and selected using high-throughput screening.
  • In vitro cytotoxicity was assessed in TNBC cell lines.
  • In vivo efficacy was evaluated in orthotopic TNBC xenograft mouse models.

Main Results:

  • CF189 demonstrated dose-dependent cytotoxicity, causing over 80% cell death in TNBC cell lines.
  • Intratumoral injection of CF189 significantly reduced tumor size in vivo at low doses (10^3 PFU).
  • An abscopal effect, shrinkage of remote tumors, was observed.

Conclusions:

  • The chimeric parapoxvirus CF189 exhibits potent in vitro and in vivo antitumor activity against triple-negative breast cancer.
  • CF189 demonstrates significant potential for clinical development as a novel therapeutic agent for TNBC.

More Related Videos

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

1.4K
Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.7K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.2K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.1K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.4K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K